PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 1, 2013, Pages 21-28

  Licciardi, Mariano ^a   Pasut, Gianfranco ^b   Amato, Giovanni ^a   Scialabba, Cinzia ^a   Mero, Anna ^b   Montopoli, Monica ^b   Cavallaro, Gennara ^a   Schiavon, Oddone ^b   Giammona, Gaetano ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c CNR   (Italy)

Author keywords

Osteoporosis; Peptide; PHEA graft copolymer; Salmon calcitonin; Supramolecular aggregates

Indexed keywords

BETA POLY(N 2 HYDROXYETHYL) GRAFT [ N 2 ETHYLENE[2 POLY(METHACRYLIC ACID SODIUM SALT)ISOBUTYRATE]]ASPARTAMIDE; CALCIUM; COMBIZYM; COPOLYMER; SALCATONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM TRANSPORT; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TEMPERATURE; MEMBRANE PERMEABILITY; MICROSCOPY; MONOLAYER CULTURE; NONHUMAN; PHARMACODYNAMICS; RAT; STATIC ELECTRICITY; SUPRAMOLECULAR CHEMISTRY; TURBIDIMETRY; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; CALCITONIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; PEPTIDES; POLYHYDROXYETHYL METHACRYLATE; POLYMETHACRYLIC ACIDS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84876947613     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.12.011     Document Type: Article

References (26)

1. L.M. Ensign, R. Cone, and J. Hanes Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers Adv. Drug Deliv. Rev. 64 2012 557 570
2. U. Bilati, E. Allemann, and E. Doelker Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles Eur. J. Pharm. Biopharm. 59 2005 375 388
3. G.P. Colombo, F. Sonvico, G. Colombo, and R. Bettini Novel platforms for oral drug delivery Pharm. Res. 26 2009 601 611
4. M. Goldberg, and I. Gomez-Orellana Challenges for the oral delivery of macromolecules Nat. Rev. Drug Discov. 2 2003 289 295
5. M. Morishita, and N.A. Peppas Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11 2006 905 910
6. D.R. Owens New horizons-alternative routes for insulin therapy Nat. Rev. Drug Discov. 1 2002 529 540
7. D. Yu, and J.R. Turner Stimulus-induced reorganization of tight junction structure: the role of membrane traffic Biochim. Biophys. Acta 1778 2008 709 716
8. S. Sadekar, and H. Ghandehari Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery Adv. Drug Deliv. Rev. 64 2012 571 588
9. B.W. Purdue, N. Tilakaratne, and P.M. Sexton Molecular pharmacology of the calcitonin receptor Recept. Channels 8 2002 243 255
10. L. Baginski, O.L. Gobbo, F. Tewes, J.J. Salomon, A.M. Healy, U. Bakowsky, and C. Ehrhardt In vitro and in vivo characterisation of PEG-lipid-based micellar complexes of salmon calcitonin for pulmonary delivery Pharm. Res. 29 2012 1425 1434
11. P. Peichl, A. Griesmacher, W. Kumpan, R. Schedl, E. Prosquil, and H. Bröll Clinical outcome of salmon calcitonin nasal spray treatment in postmenopausal women after total hip arthroplasty Gerontology 51 2005 242 252
12. M. Torres-Lugo, and N.A. Peppas Transmucosal delivery systems for calcitonin: a review Biomaterials 21 2000 1191 1196
13. C. Prego, M. Fabre, D. Torres, and M.J. Alonso Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery Pharm. Res. 23 2006 549 556
14. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima PH-sensitive microsphere delivery increases oral bioavailability of calcitonin J. Control. Release 98 2004 1 9
15. E. Lee, M.J. Lee, C.R. Park, A.Y. Kim, K.H. Chun, H.J. Hwang, D.H. Oh, S.O. Jeon, J.S. Kang, T.S. Jung, G.J. Choi, and S. Lee Preparation and characterization of salmon calcitonin-sodium triphosphate ionic complex for oral delivery J. Control. Release 143 2010 251 257
16. W.P. Cheng, C. Thompson, S.M. Ryan, T. Aguirre, L. Tetley, and D.J. Brayden In vitro and in vivo characterisation of a novel peptide delivery system: amphiphilic polyelectrolyte-salmon calcitonin nanocomplexes J. Control. Release 147 2010 289 297
17. M.A. Karsdal, K. Henriksen, A.C. Bay-Jensen, B. Molloy, M. Arnold, M.R. John, I. Byrjalsen, M. Azria, B.J. Riis, P. Qvist, and C. Christiansen Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials J. Clin. Pharmacol. 51 2011 460 471
18. G. Cavallaro, M. Licciardi, M. Di Stefano, G. Pitarresi, and G. Giammona New self-assembling polyaspartamide-based brush copolymers obtained by atom transfer radical polymerization Macromolecules 42 2009 3247 3257
19. M. Licciardi, G. Cavallaro, M. Di Stefano, C. Fiorica, and G. Giammona Polyaspartamide-graft-polymethacrylate nanoparticles for doxorubicin delivery Macromol. Biosci. 11 2011 445 454
20. G. Giammona, B. Carlisi, and S. Palazzo Reaction of α,β- poly(N-hydroxyethyl)-d,l-aspartamide with derivatives of carboxylic acids J. Polym. Sci. Polym. Chem. 25 1987 2813 2818
21. R. Mendichi, A. Giacometti Schieroni, G. Cavallaro, M. Licciardi, and G. Giammona Molecular characterization of α,β-poly(N-2-hydroxyethyl)-DL- aspartamide derivatives as potential self-assembling copolymers forming polymeric micelles Polymer 44 2003 4871 4879
22. A. Mero, M. Schiavon, F.M. Veronese, and G. Pasut A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone J. Control. Release 154 2011 27 34
23. V.D.G. Gonzales, L.M. Gugliotta, J.R. Vega, and G.R. Meira Contamination by larger particles of two almost-uniform latices: analysis by combined dynamic light scattering and turbidimetry J. Colloid Interface Sci. 285 2005 581 589
24. M.A. Llosent The effect of light absorption of particle and medium on the particle size estimation by turbidimetry J. Opt. A: Pure Appl. Opt. 1 1999 590 600
25. Guidance for Industry. Waiver of In vivo Bioavailability and Bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification system, 2000. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), February 2006. < http://www.fda.gov/cder/guidance/3618fnl.pdf >.
26. K. Park, I.C. Kwon, and K. Park Oral protein delivery: current status and future prospect React. Funct. Polym. 71 2011 280 287